As shown in Figures 7C and S6P, compared to other treatment, Gzmb+ cells were significantly accumulated in the tumor in the combo treatment group, which was indicative of cytolytic function of the combination treatment, serving as a useful predictive biomarker for efficacious responses to immunotherapy.86 This evidence concerns the gene GZMB and neoplasm.